Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 13,484 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: cGVHD Clear all
Completed Not applicable Interventional

Increasing the Use of Self Measured Home Blood Pressure Logs in the Management of Hypertension

NCT07556783
View directory record Official record
Conditions
Hypertension
Interventions
A structured, telephone-based educational outreach to encourage HBPM
Other
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 29, 2026, 10:09 AM EDT
Completed Not applicable Interventional Results available

Postoperative Telehealth Mindfulness Intervention After Spine Surgery

NCT04648683
View directory record Official record
Conditions
Chronic Low-back Pain, Postsurgical Pain, Opioid Use, Lumbar Spine Surgery
Interventions
Individual telehealth mindfulness, Group telehealth mindfulness
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 29, 2026, 10:09 AM EDT
Active, not recruiting Phase 3 Interventional

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

NCT03701282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
864
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 10:09 AM EDT
Recruiting Not applicable Interventional

Prospective Assessment of Integrative Therapies for Neuromusculoskeletal Pain (PAIN)

NCT07094282
View directory record Official record
Conditions
Chronic Pain
Interventions
Acupuncture, myofascial therapy, microcurrent therapy, LASER, extracorporeal shockwave therapy, Pulsed electromagnetic therapies, Miscellaneous integrative medicine
Other
Lead sponsor
David Moss
Federal
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 29, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vitamin D to ENhance TraUma REcovery

NCT05458024
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Vitamin D 2, Vitamin D2 Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Worcester, Massachusetts • St Louis, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 29, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

NCT02392624
View directory record Official record
Conditions
Urticaria
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
40
States / cities
Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 29, 2026, 10:09 AM EDT
Completed Phase 1 Interventional

Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes

NCT00098423
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
tanespimycin, cytarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 29, 2026, 10:09 AM EDT
Completed Phase 1 Interventional

MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

NCT00101179
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Leukemia, Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Azacitidine, Entinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 29, 2026, 10:09 AM EDT
Completed No phase listed Observational

Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection

NCT03859388
View directory record Official record
Conditions
Rejection Chronic Renal, Kidney Transplant Rejection
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction

NCT02992288
View directory record Official record
Conditions
Heart Failure
Interventions
Neladenoson bialanate (BAY1067197), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Naples, Florida • Detroit, Michigan • Jackson, Mississippi + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 29, 2026, 10:09 AM EDT
Not listed Not applicable Interventional

Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

NCT01017627
View directory record Official record
Conditions
Anemia, Mortality
Interventions
Early anemia diagnosis and treatment, No change from normal routine
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Denver, Colorado • Jacksonville, Florida • Chicago, Illinois + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 29, 2026, 10:09 AM EDT
Not listed No phase listed Observational

Observational Study of BIS in Hemodialysis Patients

NCT05381961
View directory record Official record
Conditions
Kidney Failure, Chronic, Renal Failure Chronic, Hemodialysis
Interventions
Bioimpedance spectroscopy (BIS) measurement, SOZO device
Device
Lead sponsor
ImpediMed Limited
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 29, 2026, 10:09 AM EDT
Completed Not applicable Interventional

Exercise and Pain in AYACS

NCT05562570
View directory record Official record
Conditions
AYA Cancer Survivors
Interventions
Physical activity intervention coupled with standard post-cancer directed treatment care, Standard post-cancer directed treatment care control
Behavioral · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 29, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01640951
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-Type Psoriasis
Interventions
AIN457 150 mg, AIN457 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Fresno, California • Pasadena, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 29, 2026, 10:09 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B

NCT01298037
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
11
States / cities
San Francisco, California • Boston, Massachusetts • Plymouth, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 29, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)

NCT00211445
View directory record Official record
Conditions
Chronic Central Serous Chorioretinopathy
Interventions
Photodynamic Therapy with Verteporfin, verteporfin
Procedure · Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2007 · Synced Oct 29, 2026, 10:09 AM EDT
Completed Not applicable Interventional Results available

Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study

NCT00890045
View directory record Official record
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
HeRO Vascular Access Device, Conventional ePTFE hemodialysis graft
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
22 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 29, 2026, 10:09 AM EDT
Terminated Phase 1 Interventional

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

NCT00376519
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
Interventions
cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 29, 2026, 10:09 AM EDT
Not yet recruiting Phase 2 Interventional

LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

NCT07645300
View directory record Official record
Conditions
Hypertension Treated With Antihypertensive Drugs, Chronic Kidney Disease, 3B and 4
Interventions
phase 2A Chlorthalidone, phase 2A Spironolactone, phase 2A Chlorthalidone + Spironolactone, phase 2B Chlorthalidone LD + Spironolactone LD
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 29, 2026, 10:09 AM EDT
Recruiting Not applicable Interventional

VR Mindfulness Training for Veterans With SCI

NCT06587607
View directory record Official record
Conditions
Spinal Cord Injury, Chronic Pain
Interventions
VA Compassionate Awareness Learning Module (VA CALM) a mindfulness curriculum.
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 29, 2026, 10:09 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

PRINT Trial (Platelet Rich Injection vs Needle Tenotomy)

NCT03504111
View directory record Official record
Conditions
Lateral Epicondylitis, Tendinosis, Elbow, Tennis, Elbows Tendonitis
Interventions
Percutaneous Needle Tenotomy, PRP
Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 29, 2026, 10:09 AM EDT
Completed Phase 4 Interventional

Xolair in Patients With Chronic Sinusitis

NCT00117611
View directory record Official record
Conditions
Sinusitis
Interventions
Anti-IgE antibody omalizumab or placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 29, 2026, 10:09 AM EDT
Recruiting Phase 2 Interventional

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

NCT06927999
View directory record Official record
Conditions
Urticaria Chronic
Interventions
Placebo, 0.5 mg epinephrine, 1 mg epinephrine
Drug
Lead sponsor
ARS Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glenview, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 29, 2026, 10:09 AM EDT
Terminated Phase 2 Interventional Results available

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

NCT01116232
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, rituximab, sirolimus, tacrolimus, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 29, 2026, 10:09 AM EDT